← Back to all trials
Active Not Recruiting
NCT07156149
Fabhalta Capsules Specified Drug-use Survey
Conditions: C3 Glomerulopathy
Sex: All
Ages: 0 Years – 100 Years
Healthy volunteers: No
Enrollment: 32
Sponsor: Novartis Pharmaceuticals
Location: Novartis Investigative Site Nagoya Aichi-ken
Summary
The objective of this study is to evaluate the safety and effectiveness of Fabhalta in patients with C3 glomerulopathy in clinical practice.
Eligibility Criteria
Inclusion Criteria:
* All patients who have used Fabhalta for C3 glomerulopathy (including patients with recurrent C3 glomerulopathy post renal transplant).
Exclusion Criteria:
* Use of iptacopan for an indication not yet approved under the Clinical Trials Act or GCP (e.g., patient-requested medical treatment, investigator-initiated clinical trial)
Source: ClinicalTrials.gov (NCT07156149). StuddyBuddy aggregates publicly available trial information.
